The Impact of Antenatal Steroid Exposure on the Intrarenal Renin-Angiotensin

产前类固醇暴露对肾内肾素-血管紧张素的影响

基本信息

  • 批准号:
    8712516
  • 负责人:
  • 金额:
    $ 16.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-08-20 至 2016-01-31
  • 项目状态:
    已结题

项目摘要

Substantial evidence demonstrates that prenatal events have effects on development resulting in pathophysiological consequences in adulthood. The outcome of some of these effects is a predisposition to certain diseases including hypertension. Our data from the previous funding period demonstrate that prenatal exposure to clinically relevant doses of glucocorticoids at a critical stage of gestation (peak of nephrogenesis) reduces nephron number, impairs excretion of a salt load (that is gender dependent) and elevates blood pressure in adulthood. Although knowledge of the mechanisms whereby sodium excretion is altered is nearly nonexistent, alterations in the intrarenal renin-angiotensin system (RAS) which we have reported may be involved. In addition, it is not known if the alterations in renal development and the intrarenal RAS result in greater susceptibility to renal damage and greater loss of function following a second insult. Therefore this proposed project has two objectives. The first is to determine if the mechanisms responsible for the reduced ability to excrete a sodium load involve alterations in the receptors/signaling pathways that respond to the angiotensin peptides in the kidney. The second is to ascertain if prenatal betamethasone exposure results in higher risk for additional renal damage from an adverse event after birth. We will study sheep, because they are similar to humans in terms of the timing of nephrogenesis relative to stage of gestation and because these animals provide sufficient quantities of renal tissue for our in vitro studies. We hypothesize that: 1) the mechanisms involved in the reduced ability to excrete a sodium load include reductions in the ability of Ang peptides to activate signaling pathways associated with natriuresis; and, 2) prenatal betamethasone exposure results in greater risk for renal damage and reductions in function following a second insult afterbirth. We will use specific assays to measure the angiotensin peptides and key components in the signaling pathways activated by them associated with natriuresis. Binding assays will be used to assess receptors for these peptides. We will use unilateral nephrectomy or obesity (induced by voluntary overeating) as second "hits" and evaluate renal function and markers of renal damage to establish if there is a predisposing relationship between prenatal betamethasone and subsequent renal injury. Understanding more about the impact of antenatal glucocorticoids on renal function and susceptibility to renal damage in adulthood is important because of the widespread use of glucocorticoids in Obstetrics today. Our studies may identify a population at greater risk for renal disease and hypertension as they mature which could result in approaches for monitoring this at risk population and early intervention to prevent premature deterioration of renal function in adulthood.
大量证据表明,产前事件对发育有影响,导致成年后产生病理生理学后果。其中一些影响的结果是易患某些疾病,包括高血压。我们上一个资助期的数据表明,在妊娠关键阶段(肾生成高峰)产前接触临床相关剂量的糖皮质激素会减少肾单位数量,损害盐负荷的排泄(即性别依赖性)并升高成年期的血压。尽管对钠排泄改变的机制的了解几乎不存在,但我们报道的肾内肾素-血管紧张素系统(RAS)的改变可能与此有关。此外,尚不清楚肾脏发育和肾内 RAS 的改变是否会导致二次损伤后更容易受到肾损伤和更大的功能丧失。因此,该拟议项目有两个目标。首先是确定导致钠负荷排泄能力降低的机制是否涉及对肾脏中血管紧张素肽做出反应的受体/信号通路的改变。第二个是确定产前倍他米松暴露是否会导致出生后不良事件导致额外肾损伤的风险更高。我们将研究绵羊,因为它们在相对于妊娠阶段的肾发生时间方面与人类相似,并且因为这些动物为我们的体外研究提供了足够数量的肾组织。我们假设:1)排泄钠负荷能力降低的机制包括血管紧张肽激活与尿钠排泄相关的信号通路的能力降低; 2) 产前接触倍他米松会导致肾损伤和产后第二次损伤后功能下降的风险更大。我们将使用特定的检测方法来测量血管紧张素肽以及由它们激活的与尿钠排泄相关的信号通路中的关键成分。结合测定将用于评估这些肽的受体。我们将使用单侧肾切除术或肥胖(由自愿暴饮暴食引起)作为第二次“打击”,并评估肾功能和肾损伤标志物,以确定产前倍他米松与随后的肾损伤之间是否存在易感关系。由于当今产科广泛使用糖皮质激素,更多地了解产前糖皮质激素对肾功能和成年期肾损伤易感性的影响非常重要。我们的研究可能会确定成年后患肾病和高血压的风险较高的人群,这可能会产生监测这一高危人群的方法,并进行早期干预,以防止成年后肾功能过早恶化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES C. ROSE其他文献

Performance of task functions by A.D.A. dietetic technicians
  • DOI:
    10.1016/s0002-8223(21)39276-8
  • 发表时间:
    1980-06-01
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    JAMES C. ROSE;KATHLEEN ZOLBER;IRMA VYHMEISTER;DAVID ABBEY;KENNETH BURKE
  • 通讯作者:
    KENNETH BURKE

JAMES C. ROSE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES C. ROSE', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    7005940
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
Antenatal Steroids Exposure and Adipose Tissue Renin-Angiotensin-System Function
产前类固醇暴露与脂肪组织肾素血管紧张素系统功能
  • 批准号:
    8381682
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
Antenatal Steroid Exposure and Neural Control of Blood Pressure
产前类固醇暴露与血压的神经控制
  • 批准号:
    8381684
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
Antenatal Steroids and Cardiometabolic Risk
产前类固醇和心脏代谢风险
  • 批准号:
    8712519
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
The Impact of Antenatal Steroid Exposure on the Intrarenal Renin-Angiotensin
产前类固醇暴露对肾内肾素-血管紧张素的影响
  • 批准号:
    9264075
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
The Impact of Antenatal Steroid Exposure on the Intrarenal Renin-Angiotensin
产前类固醇暴露对肾内肾素-血管紧张素的影响
  • 批准号:
    8918005
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
Critique of the Overall Program Project Application
总体方案立项申请评审
  • 批准号:
    7012101
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
Antenatal Steroids and Cardiometabolic Risk
产前类固醇和心脏代谢风险
  • 批准号:
    8381685
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
ANIMAL CORE
动物核心
  • 批准号:
    8381688
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:
Prenatal Events-Postnatal Consequences
产前事件-产后后果
  • 批准号:
    8712515
  • 财政年份:
    2005
  • 资助金额:
    $ 16.82万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 16.82万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 16.82万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 16.82万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 16.82万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 16.82万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 16.82万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 16.82万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 16.82万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 16.82万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 16.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了